Sanofi-aventis Canada Enters Into Licensing Agreement With Intelliject
Sanofi-aventis Canada has entered into a licensing agreement with Intelliject for a novel epinephrine auto injector for the emergency treatment of allergic reactions (anaphylaxis) in North America (US
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.